Non-stimulant ADHD medications are a class of drugs that treat attention deficit hyperactivity disorder without the stimulant properties of medications like Adderall or Ritalin. The FDA has approved four of them: atomoxetine (Strattera), viloxazine (Qelbree), guanfacine (Intuniv), and clonidine (Kapvay). They work through different brain pathways than stimulants, carry no risk of dependence, and are typically considered when stimulants cause intolerable side effects or aren’t a good fit.
How Non-Stimulants Differ From Stimulants
Stimulants like methylphenidate and amphetamines are generally more potent for ADHD symptoms. A large analysis published in The Lancet Psychiatry found that amphetamines reduced ADHD symptoms in children and adolescents with an effect size of 1.02 compared to placebo, while atomoxetine (the most studied non-stimulant) came in at 0.56. That doesn’t mean non-stimulants are weak. It means they work noticeably but more modestly, and the tradeoff often comes with a more favorable side effect profile.
The biggest practical difference is timing. Stimulants typically start working within an hour of the first dose. Non-stimulants build up gradually in your system and may take several weeks before you notice the full effect. This slower onset means patience is part of the process, but it also means the medication works around the clock rather than wearing off in the afternoon or evening.
Non-stimulants also don’t carry the same concerns about abuse potential. Because they don’t produce the rapid dopamine surge that stimulants do, they aren’t classified as controlled substances. This makes them easier to prescribe and refill, and a better option for people with a history of substance use.
The Four FDA-Approved Options
Atomoxetine (Strattera)
Atomoxetine was the first non-stimulant approved for ADHD and remains the most widely prescribed. It works by blocking the reuptake of norepinephrine, a chemical messenger involved in attention and impulse control. In the prefrontal cortex, the brain region responsible for organization and focus, it also indirectly increases dopamine levels. It’s approved for patients aged 6 and older, including adults.
The most common side effects are drowsiness, nausea, and decreased appetite. Atomoxetine does carry two important safety warnings. First, in clinical trials involving over 2,200 children and adolescents, it was associated with a small increase in suicidal thoughts early in treatment: 0.4% of patients on atomoxetine experienced suicidal ideation compared to none on placebo. No suicides occurred. Second, rare cases of severe liver injury have been reported after starting the medication, most within the first 120 days. Signs like yellowing of the skin or eyes would mean stopping the drug immediately.
Viloxazine (Qelbree)
Viloxazine is the newest non-stimulant, approved for children and teens in 2021 and for adults in 2022. It blocks norepinephrine reuptake like atomoxetine but also directly affects serotonin activity, which is why it’s classified as a serotonin-norepinephrine modulating agent. Its approval was backed by four large clinical trials involving more than 1,000 pediatric patients. Interestingly, viloxazine produces mild stimulant-like effects in the central nervous system without the dependence risk that comes with actual stimulants.
Guanfacine (Intuniv)
Guanfacine belongs to a different class called alpha-2 agonists. Rather than targeting norepinephrine reuptake, it activates specific receptors in the prefrontal cortex that strengthen attention signals. The extended-release version (Intuniv) was approved for ADHD in children aged 6 to 17 in 2009. It tends to be particularly helpful for hyperactivity and impulsivity rather than pure inattention. Common side effects include fatigue, headache, and dry mouth. Of the two alpha agonists, guanfacine is generally less sedating, which makes it a more practical choice for many patients.
Clonidine (Kapvay)
Clonidine works through the same alpha-2 agonist mechanism as guanfacine and was approved for ADHD in children aged 6 to 17 in 2010. It’s more sedating than guanfacine and more likely to lower blood pressure and cause dizziness. In ADHD treatment, the most common side effects reported in trials were drowsiness (31%) and dizziness (17%). Because of the sedation, clonidine is sometimes prescribed specifically when sleep problems accompany ADHD, turning a side effect into an advantage. Both alpha agonists have been used in their shorter-acting forms for years to manage hyperactive or disruptive behavior in younger children.
Who Non-Stimulants Work Best For
Non-stimulants fill several important gaps. If stimulants cause anxiety, insomnia, significant appetite loss, or tics, switching to a non-stimulant often resolves those problems. People with a history of substance use disorder are frequently started on non-stimulants to avoid the abuse potential of stimulants altogether. They’re also useful when stimulants work during the day but wear off too quickly, since non-stimulants provide more consistent coverage.
Some clinicians combine a stimulant with a non-stimulant, particularly an alpha agonist, to cover different symptom dimensions. For example, a stimulant might handle focus and concentration while guanfacine or clonidine addresses impulsivity or evening restlessness.
The Shared Side Effect Pattern
Unlike stimulants, which commonly cause appetite suppression and insomnia, non-stimulants tend to push in the opposite direction. Across all four medications, the most frequently reported side effects are drowsiness and fatigue. An analysis of adverse events reported to the FDA found that drowsiness and fatigue were consistently among the top complaints, along with reports of the medication simply not being effective enough (roughly 10 to 14% of reports).
This pattern means non-stimulants are less likely to interfere with sleep or eating, but the trade-off is that you may feel sluggish, especially during the first few weeks. Most people find that sedation improves as the body adjusts. Taking the medication in the evening can help if daytime drowsiness is an issue.
Off-Label Alternatives
Beyond the four FDA-approved options, some medications are prescribed off-label for ADHD. The most common is bupropion, an antidepressant that affects dopamine and norepinephrine. In a randomized trial, 53% of adults taking bupropion met the threshold for an ADHD treatment response at 8 weeks, compared to 31% on placebo. Its effect size of 0.6 is comparable to atomoxetine. Bupropion can be a practical choice when someone has both depression and ADHD, since it can address both with a single medication.
What to Expect When Starting
The adjustment period for non-stimulants is longer than for stimulants. With atomoxetine and viloxazine, it can take 4 to 6 weeks to see the full benefit. Alpha agonists may work somewhat faster for behavioral symptoms but still require gradual dose increases over several weeks. This is the most important thing to know going in: if a non-stimulant doesn’t seem to be doing much after the first week or two, that’s expected. The medication needs time to reach a steady level in your system.
Stopping non-stimulants also requires a gradual taper, especially with alpha agonists. Abruptly discontinuing clonidine or guanfacine can cause a rebound spike in blood pressure. Your prescriber will typically step the dose down over a period of days.